BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 32758349)

  • 21. Clinicopathological and genomic comparisons between different histologic components in combined small cell lung cancer and non-small cell lung cancer.
    Lin MW; Su KY; Su TJ; Chang CC; Lin JW; Lee YH; Yu SL; Chen JS; Hsieh MS
    Lung Cancer; 2018 Nov; 125():282-290. PubMed ID: 30429033
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Genomic and transcriptomic profiling of combined small-cell lung cancer through microdissection: unveiling the transformational pathway of mixed subtype.
    Ma W; Zhou T; Song M; Liu J; Chen G; Zhan J; Ji L; Luo F; Gao X; Li P; Xia X; Huang Y; Zhang L
    J Transl Med; 2024 Feb; 22(1):189. PubMed ID: 38383412
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Transformation of lung adenocarcinoma to small cell lung carcinoma in the setting of tyrosine kinase inhibitor therapy: Cytological approach of a clinically challenging phenomenon.
    El Hussein S; Khader SN
    Diagn Cytopathol; 2019 Aug; 47(8):845-850. PubMed ID: 31017747
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Outcome of patients with lung adenocarcinoma with transformation to small-cell lung cancer following tyrosine kinase inhibitors treatment: A systematic review and pooled analysis.
    Roca E; Gurizzan C; Amoroso V; Vermi W; Ferrari V; Berruti A
    Cancer Treat Rev; 2017 Sep; 59():117-122. PubMed ID: 28806542
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Evidence, Mechanism, and Clinical Relevance of the Transdifferentiation from Lung Adenocarcinoma to Squamous Cell Carcinoma.
    Hou S; Zhou S; Qin Z; Yang L; Han X; Yao S; Ji H
    Am J Pathol; 2017 May; 187(5):954-962. PubMed ID: 28284717
    [TBL] [Abstract][Full Text] [Related]  

  • 26. An EGFR-mutated Lung Adenocarcinoma Undergoing Squamous Cell Carcinoma Transformation Exhibited a Durable Response to Afatinib.
    Sato M; Matsui A; Shimoyama Y; Omote N; Morise M; Hase T; Tanaka I; Suzuki K; Hasegawa Y
    Intern Med; 2018 Dec; 57(23):3429-3432. PubMed ID: 30101911
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Large-Cell Neuroendocrine Carcinoma of the Lung: A Population-Based Study.
    Kinslow CJ; May MS; Saqi A; Shu CA; Chaudhary KR; Wang TJC; Cheng SK
    Clin Lung Cancer; 2020 Mar; 21(2):e99-e113. PubMed ID: 31601526
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Hyperprogressive Disease in Lung Cancer with Transformation of Adenocarcinoma to Small-cell Carcinoma during Pembrolizumab Therapy.
    Okeya K; Kawagishi Y; Muranaka E; Izumida T; Tsuji H; Takeda S
    Intern Med; 2019 Nov; 58(22):3295-3298. PubMed ID: 31327828
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Advances in the Transformation to Small Cell Lung Cancer from Non-small Cell Lung Cancer Following Acquired Drug-resistance to EGFR Tyrosine Kinase Inhibitors].
    Zhang W; Li Y; Wu D
    Zhongguo Fei Ai Za Zhi; 2017 Oct; 20(10):720-726. PubMed ID: 29061221
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Heterogeneity in Immune Marker Expression after Acquisition of Resistance to EGFR Kinase Inhibitors: Analysis of a Case with Small Cell Lung Cancer Transformation.
    Suda K; Murakami I; Yu H; Kim J; Ellison K; Rivard CJ; Mitsudomi T; Hirsch FR
    J Thorac Oncol; 2017 Jun; 12(6):1015-1020. PubMed ID: 28193529
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical features of unresectable high-grade lung neuroendocrine carcinoma diagnosed using biopsy specimens.
    Shimada Y; Niho S; Ishii G; Hishida T; Yoshida J; Nishimura M; Yoh K; Goto K; Ohmatsu H; Ohe Y; Nagai K
    Lung Cancer; 2012 Mar; 75(3):368-73. PubMed ID: 21920624
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Histological transformation after acquired resistance to epidermal growth factor tyrosine kinase inhibitors.
    Shao Y; Zhong DS
    Int J Clin Oncol; 2018 Apr; 23(2):235-242. PubMed ID: 29110101
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Transformation to large cell neuroendocrine carcinoma as acquired resistance mechanism of EGFR tyrosine kinase inhibitor.
    Kogo M; Shimizu R; Uehara K; Takahashi Y; Kokubo M; Imai Y; Tomii K
    Lung Cancer; 2015 Nov; 90(2):364-8. PubMed ID: 26384434
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparison of four DLL3 antibodies performance in high grade neuroendocrine lung tumor samples and cell cultures.
    Brcic L; Kuchler C; Eidenhammer S; Pabst D; Quehenberger F; Gazdar AF; Popper H
    Diagn Pathol; 2019 May; 14(1):47. PubMed ID: 31109352
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Research Advances on Transformation to Small Cell Lung Cancer].
    Zhang S; Li S; Cui Y; Cheng Y
    Zhongguo Fei Ai Za Zhi; 2021 Oct; 24(10):729-733. PubMed ID: 34696545
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The differences of biological behavior based on the clinicopathological data between resectable large-cell neuroendocrine carcinoma and small-cell lung carcinoma.
    Kinoshita T; Yoshida J; Ishii G; Aokage K; Hishida T; Nagai K
    Clin Lung Cancer; 2013 Sep; 14(5):535-40. PubMed ID: 23792008
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Large cell neuroendocrine carcinoma of the lung: a histologic and immunohistochemical study of 22 cases.
    Jiang SX; Kameya T; Shoji M; Dobashi Y; Shinada J; Yoshimura H
    Am J Surg Pathol; 1998 May; 22(5):526-37. PubMed ID: 9591721
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Transformation into large-cell neuroendocrine carcinoma associated with acquired resistance to erlotinib in nonsmall cell lung cancer.
    Lim JU; Woo IS; Jung YH; Byeon JH; Park CK; Kim TJ; Kim HR
    Korean J Intern Med; 2014 Nov; 29(6):830-3. PubMed ID: 25378985
    [No Abstract]   [Full Text] [Related]  

  • 39. Case report: small cell transformation and metastasis to the breast in a patient with lung adenocarcinoma following maintenance treatment with epidermal growth factor receptor tyrosine kinase inhibitors.
    Lin Q; Cai GP; Yang KY; Yang L; Chen CS; Li YP
    BMC Cancer; 2016 Aug; 16():593. PubMed ID: 27488410
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Concurrent RB1 and TP53 Alterations Define a Subset of EGFR-Mutant Lung Cancers at risk for Histologic Transformation and Inferior Clinical Outcomes.
    Offin M; Chan JM; Tenet M; Rizvi HA; Shen R; Riely GJ; Rekhtman N; Daneshbod Y; Quintanal-Villalonga A; Penson A; Hellmann MD; Arcila ME; Ladanyi M; Pe'er D; Kris MG; Rudin CM; Yu HA
    J Thorac Oncol; 2019 Oct; 14(10):1784-1793. PubMed ID: 31228622
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.